Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 034-039
DOI: 10.1055/s-0042-1742658
Review Article

Gynecologic Oncology: On the Shoulders of Giants

Rohini Kulkarni
1   Department of Gynaecologic Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sudeep Gupta 
2   Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Amita Maheshwari 
1   Department of Gynaecologic Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Gynecologic oncology is considered a new field, but its roots are buried deep in the past. As with other tumors, the earliest progress in modern times started with anesthesia and surgery. This was followed by landmark achievements in pathology, cytology, radiotherapy, chemotherapy, tumor virology, generation of high-quality evidence, and, more recently, genetics and genomics. Some of the most notable progresses in gynecologic cancers have been made by integrating the expertise of various specialties in multimodality management approaches. In this article we review the most important milestones in the history of gynecologic oncology and acknowledge the contributions of pioneers who made these possible.

Keywords

gynecologic oncology - history - treatment


Publication History

Article published online:
15 February 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sushruta, Bhishagratha KL. An English Translation of the Sushrutha Samhita: Based on Original Sanskrit Text. 2nd edition.. Varanasi: Chowkhamba Sanskrit; 1963
    Google Scholar
  • 2 Charaka, Kaviratna AC. Charaka Samhita: Translated into English. Varanasi: Choukambha Sanskrit; 1991
    Google Scholar
  • 3 Chisholm H. Soranus. In: Encyclopaedia Britannica. Vol. 25. 11th edition.. Cambridge University Press; 1911: 430
    Google Scholar
  • 4 Sims M. The Story of My Life. New York: Appleton; 1884
    Google Scholar
  • 5 Dorland NWA. The American Illustrated Medical Dictionary. W.B. Saunders Company; 1917: 272
    Google Scholar
  • 6 Fulop-Miller R. Triumph Over Pain. New York, NY: The Literary Guild of America, Inc.; 1938
    CrossrefGoogle Scholar
  • 7 Simpson JY. Cases of excision of the cervix uteri for carcinomatous disease. Dub Quart J Med Sci 1846; 2: 352-372
    CrossrefGoogle Scholar
  • 8 Ebert A. [30 January 1878: Wilhelm Alexander Freund and the abdominal extirpation of the uterus]. Zentralbl Gynäkol 1989; 111 (14) 995-1003
    PubMedGoogle Scholar
  • 9 Dursun P, Gultekin M, Ayhan A. The history of radical hysterectomy. J Low Genit Tract Dis 2011; 15 (03) 235-245
    CrossrefPubMedGoogle Scholar
  • 10 Schauta F. Indication and technik der vaginalen Totalexstirpation. zeitschrift fur Heilkunde; 1891
    PubMedGoogle Scholar
  • 11 Mitra S. Extraperitoneal lymphadenectomy and radical vaginal hysterectomy for cancer of the cervix (Mitra technique). Am J Obstet Gynecol 1959; 78 (01) 191-196
    CrossrefPubMedGoogle Scholar
  • 12 Wertheim E. Zur frage der radical operation beim uterus krebs. Arch Gynakol 1900; 61: 627
    CrossrefGoogle Scholar
  • 13 Speert H. Obstetric and Gynecologic Milestones; Essays in Eponymy. New York: Macmillan; 1958
    Google Scholar
  • 14 Clark JG. A more radical method of performing hysterectomy for cancer of the uterus. Bull Johns Hopkins Hosp 1895; 6: 120
    Google Scholar
  • 15 Meigs JV. Tumors of the Female Pelvic Organs. New York: The Macmillan Company; 1934
    Google Scholar
  • 16 Schorge JO, Bregar AJ, Durfee J, Berkowitz RS. Meigs to modern times: the evolution of debulking surgery in advanced ovarian cancer. Gynecol Oncol 2018; 149 (03) 447-454
    CrossrefPubMedGoogle Scholar
  • 17 Meigs JV. Cancer of the ovary. N Engl J Med 1939; 220: 545-553
    CrossrefGoogle Scholar
  • 18 Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42: 101-104
    PubMedGoogle Scholar
  • 19 Nelson H, Sargent DJ, Wieand HS. et al; Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med 2004; 350 (20) 2050-2059
    CrossrefPubMedGoogle Scholar
  • 20 Walker JL, Piedmonte MR, Spirtos NM. et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009; 27 (32) 5331-5336
    CrossrefPubMedGoogle Scholar
  • 21 Janda M, Gebski V, Davies LC. et al. Effect of total laparoscopic hysterectomy vs total abdominal hysterectomy on disease-free survival among women with stage I endometrial cancer: a randomized clinical trial. JAMA 2017; 317 (12) 1224-1233
    CrossrefPubMedGoogle Scholar
  • 22 Ramirez PT, Frumovitz M, Pareja R. et al. Minimally invasive versus abdominal radical hysterectomy for cervical cancer. N Engl J Med 2018; 379 (20) 1895-1904
    CrossrefPubMedGoogle Scholar
  • 23 Coleman RL, Spirtos NM, Enserro D. et al. Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 2019; 381 (20) 1929-1939
    CrossrefPubMedGoogle Scholar
  • 24 Shi T, Zhu J, Feng Y. et al. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021; 22 (04) 439-449
    CrossrefPubMedGoogle Scholar
  • 25 Harter P, Sehouli J, Vergote I. et al; DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 2021; 385 (23) 2123-2131
    CrossrefPubMedGoogle Scholar
  • 26 Cantrill V. The realities of radium. Nat Chem 2018; 10 (08) 898
    CrossrefPubMedGoogle Scholar
  • 27 Obituary: E. H. GRUBBE, M.D., F.A.C.P. BMJ 1960; 2: 609
    CrossrefGoogle Scholar
  • 28 London Health Sciences Centre. Celebrating the 60th anniversary of the world's first cancer treatment with Cobalt-60 radiation. https://www.lhsc.on.ca/about-lhsc/about-lhsc-129#:~:text=LONDON%2C%20ON%20%E2%80%93%20On%20October%2027,in%20the%20field%20of%20radiotherapy
    Google Scholar
  • 29 Banerjee S, Mahantshetty U, Shrivastava S. Brachytherapy in India - a long road ahead. J Contemp Brachytherapy 2014; 6 (03) 331-335
    CrossrefPubMedGoogle Scholar
  • 30 Munshi A, Ganesh T, Mohanti BK. Radiotherapy in India: history, current scenario and proposed solutions. Indian J Cancer 2019; 56 (04) 359-363
    CrossrefPubMedGoogle Scholar
  • 31 Shrivastava S. Brachytherapy–perspectives in evolution: take it with a bag of salt. J Cancer Res Ther 2005; 1 (02) 73-74
    CrossrefPubMedGoogle Scholar
  • 32 Landoni F, Maneo A, Colombo A. et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350 (9077): 535-540
    CrossrefPubMedGoogle Scholar
  • 33 Rose PG, Bundy BN, Watkins EB. et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340 (15) 1144-1153
    CrossrefPubMedGoogle Scholar
  • 34 Morris M, Eifel PJ, Lu J. et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340 (15) 1137-1143
    CrossrefPubMedGoogle Scholar
  • 35 de Boer SM, Powell ME, Mileshkin L. et al; PORTEC Study Group. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20 (09) 1273-1285
    CrossrefPubMedGoogle Scholar
  • 36 Wortman BG, Creutzberg CL, Putter H. et al; PORTEC Study Group. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer 2018; 119 (09) 1067-1074
    CrossrefPubMedGoogle Scholar
  • 37 Creutzberg CL, Nout RA, Lybeert MLM. et al; PORTEC Study Group. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma. Int J Radiat Oncol Biol Phys 2011; 81 (04) e631-e638
    CrossrefPubMedGoogle Scholar
  • 38 Jenkins D. A brief history of cervical cancer. In: Human Papillomavirus: Proving and Using a Viral Cause for Cancer. Massachusetts, USA: Elsevier; 2019: 1-12
    Google Scholar
  • 39 Hinselmann H. Verbesserung der Inspektionsmöglichkeit von Vulva, Vagina und Portio. Munch Med Wochenschr 1925; 77: 1733 [In German]
    Google Scholar
  • 40 Herbert T. Diagnosis of uterine cancer by the vaginal smear. Yale J Biol Med 1943; 15 (06) 924
    Google Scholar
  • 41 Papanicolaou GN. A new procedure for staining vaginal smears. Science 1942; 95 (2469): 438-439
    CrossrefPubMedGoogle Scholar
  • 42 Ayre JE. Cancer Cytology of the Uterus. New York: Grune Stratton; 1951
    Google Scholar
  • 43 https://www.nobelprize.org/prizes/medicine/2008/hausen/facts/ The Nobel Prize: The Nobel Prize in physiology or medicine
  • 44 Ehlrich P, Goder R. Chemotherapie. Handbuch der pathogenen Mikroorganismen 1913; 3: 337-374
    Google Scholar
  • 45 Goodman LS, Wintrobe MM. et al. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc 1946; 132 (03) 126-132
    CrossrefPubMedGoogle Scholar
  • 46 Dixit V. Unknown facets of “Not so well-known scientist” Dr. Y Subbarow: a great scientist, who did not receive the Nobel Prize. J Marine Med Soc 2018; 20 (02) 141-144
    CrossrefGoogle Scholar
  • 47 DeVita Jr VT, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68 (21) 8643-8653
    CrossrefPubMedGoogle Scholar
  • 48 Rosenberg B, Vancamp L, Krigas T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 1965; 205 (4972): 698-699
    CrossrefPubMedGoogle Scholar
  • 49 Rosenberg B, VanCamp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumour agents. Nature 1969; 222 (5191): 385-386
    CrossrefPubMedGoogle Scholar
  • 50 Young RC, Von Hoff DD, Gormley P. et al. cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep 1979; 63 (9-10): 1539-1544
    Google Scholar
  • 51 Conte PF, Bruzzone M, Chiara S. et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4 (06) 965-971
    CrossrefPubMedGoogle Scholar
  • 52 Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971; 93 (09) 2325-2327
    CrossrefPubMedGoogle Scholar
  • 53 Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277 (5698): 665-667
    CrossrefPubMedGoogle Scholar
  • 54 McGuire WP, Rowinsky EK, Rosenshein NB. et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111 (04) 273-279
    CrossrefPubMedGoogle Scholar
  • 55 McGuire WP, Hoskins WJ, Brady MF. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334 (01) 1-6
    CrossrefPubMedGoogle Scholar
  • 56 Ozols RF, Bundy BN, Greer BE. et al; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21 (17) 3194-3200
    CrossrefPubMedGoogle Scholar
  • 57 du Bois A, Lück HJ, Meier W. et al. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie. Semin Oncol 1997; 24 (4, Suppl 11): S11–S33 S11-S28
    PubMedGoogle Scholar
  • 58 DeVita Jr VT. The evolution of therapeutic research in cancer. N Engl J Med 1978; 298 (16) 907-910
    CrossrefPubMedGoogle Scholar
  • 59 Hortobágyi GN. Bernard Fisher: a pioneer moves on. Oncologist 2020; 25 (01) 89-90
    CrossrefGoogle Scholar
  • 60 Griffiths CT, Grogan RH, Hall TC. Advanced ovarian cancer: primary treatment with surgery, radiotherapy, and chemotherapy. Cancer 1972; 29 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 61 Vergote I, Tropé CG, Amant F. et al; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group, NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363 (10) 943-953
    CrossrefPubMedGoogle Scholar
  • 62 Gupta S, Maheshwari A, Parab P. et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol 2018; 36 (16) 1548-1555
    CrossrefPubMedGoogle Scholar
  • 63 Kenter G, Greggi S, Vergote I. et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994. J Clin Oncol 2019; 37 (15, suppl): DOI: 10.1200/JCO.2019.37.15_suppl.5503.
    CrossrefGoogle Scholar
  • 64 James Lind and Scurvy: The First Clinical Trial in History? . https://www.bbvaopenmind.com/en/science/leading-figures/james-lind-and-scurvy-the-first-clinical-trial-in-history/ Accessed January 18, 2022
    Google Scholar
  • 65 Fisher RA. The arrangement of field experiments. J Ministry of Agriculture of Great Britain 1926; 33: 503-513
    Google Scholar
  • 66 Hill AB. Principles of Medical Statistics. London: The Lancet; 1937
    Google Scholar
  • 67 Hall JM, Lee MK, Newman B. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250 (4988): 1684-1689
    CrossrefPubMedGoogle Scholar
  • 68 Wooster R, Neuhausen SL, Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265 (5181): 2088-2090
    CrossrefPubMedGoogle Scholar
  • 69 Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA I- mutation carriers: Breast Cancer Linkage Consortium. Am J Hum Genet 1995; 56: 265-271
    PubMedGoogle Scholar
  • 70 Farmer H, McCabe N, Lord CJ. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917-921
    CrossrefPubMedGoogle Scholar
  • 71 Bryant HE, Schultz N, Thomas HD. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434 (7035): 913-917
    CrossrefPubMedGoogle Scholar
  • 72 Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun 1963; 11 (01) 39-43
    CrossrefPubMedGoogle Scholar